|
37 Companies |
|
62 Products |
|
62 Products |
|
62 Mechanisms of Action |
|
5 Trials |
|
685 News |
|
| «12...234567891011121314» |
- Enrollment closed: Urinary Incontinence in an Inpatient Rehab Unit (clinicaltrials.gov) - Aug 6, 2012
P1, N=15, Active, not recruiting, Sponsor: Anne Deutsch
Not yet recruiting --> Active, not recruiting
- Clinical: 5-Year Objective and Subjective Results of a Mid-Urethral Sling (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=150, Recruiting, Sponsor: Atlantic Health System
- Trial completion: A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=150, Completed, Sponsor: Atlantic Health System
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Trial completion: Prospective Cohort Study of Robotic Assisted Laparoscopic Sacrocolpopexy Using MPATHY Restorelle Mesh (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=120, Completed, Sponsor: Atlantic Health System
Recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment closed: CEASe: Clinical Evaluation of Ajust (clinicaltrials.gov) - Jul 31, 2012
P=N/A, N=150, Active, not recruiting, Sponsor: C. R. Bard
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Clinical: Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use (clinicaltrials.gov) - Jul 22, 2012
P=N/A, N=1, Active, not recruiting, Sponsor: Kenneth Peters, MD
- ||| Enrollment open: Virtue (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=53, Recruiting, Sponsor: Coloplast A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Jul 9, 2012
P4, N=150, Active, not recruiting, Sponsor: Kirby Institute
- desmopressin / Generic mfg.
Enrollment open: Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study (clinicaltrials.gov) - Jul 9, 2012
P4, N=50, Recruiting, Sponsor: University Hospital, Ghent
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- || New P2/3 trial: Behavioral Intervention Program and Vaginal Cones on SUI (clinicaltrials.gov) - Jun 25, 2012
P2/3, N=60, Completed, Sponsor: Mashhad University of Medical Sciences
- Trial completion: Acupuncture for Urinary Incontinence (clinicaltrials.gov) - Jun 21, 2012
P2, N=127, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Enrollment closed: Beacon: Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=160, Active, not recruiting, Sponsor: Ethicon Endo-Surgery
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open: BLISS: Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study (clinicaltrials.gov) - Jun 11, 2012
P2, N=70, Recruiting, Sponsor: Austin Health
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment open: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=50, Recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: DERENEDIAB: Renal Denervation in Diabetic Nephropathy (clinicaltrials.gov) - Jun 3, 2012
P4, N=120, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change: Over Active Bladder Instillation Study - Botox (clinicaltrials.gov) - May 28, 2012
P3, N=100, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting N=70 --> 100
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Over Active Bladder Instillation Study - Botox (clinicaltrials.gov) - May 28, 2012
P3, N=100, Completed, Sponsor: Mayo Clinic
N=70 --> 100 Active, not recruiting --> Completed
- ||| UISH001 / Beech Tree Labs
Enrollment change: Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence (clinicaltrials.gov) - May 24, 2012
P1/2, N=94, Completed, Sponsor: Beech Tree Labs, Inc.
Active, not recruiting --> Completed N=60 --> 94
- eplerenone / Generic mfg.
Enrollment change: Eplerenone, ACE Inhibition and Albuminuria (clinicaltrials.gov) - May 24, 2012
P2, N=30, Completed, Sponsor: Radboud University
N=60 --> 94 N=72 --> 30
- |||| UISH001 / Beech Tree Labs
Trial completion: Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence (clinicaltrials.gov) - May 24, 2012
P1/2, N=94, Completed, Sponsor: Beech Tree Labs, Inc.
N=72 --> 30 Active, not recruiting --> Completed
- eplerenone / Generic mfg.
Trial completion: Eplerenone, ACE Inhibition and Albuminuria (clinicaltrials.gov) - May 24, 2012
P2, N=30, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed
- New P1 trial: SUIPT: The Effect of Pre-operative Pelvic Floor Muscle Exercise on Surgical Outcomes in Women With Stress Urinary Incontinence (clinicaltrials.gov) - May 16, 2012
P1, N=400, Recruiting, Sponsor: Queen's University
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P3 trial: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 15, 2012
P3, N=185, Active, not recruiting, Sponsor: Allergan
- Trial completion: Prospective Evaluation of Keat Electrostimulator in the Auto-reeducation of Female Urinary Incontinence (clinicaltrials.gov) - May 15, 2012
P=N/A, N=450, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Completed Recruiting --> Completed
- | New P2 trial: TULIP: Translating Unique Learning for Incontinence Prevention (clinicaltrials.gov) - May 14, 2012
P2, N=600, Active, not recruiting, Sponsor: University of Michigan
- Simulect (basiliximab) / Novartis
Enrollment closed: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (clinicaltrials.gov) - May 14, 2012
P2, N=17, Active, not recruiting, Sponsor: Indiana University School of Medicine
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Enrollment closed: Self-Care to Prevent Birth-Related Urinary Incontinence in Diverse Women (clinicaltrials.gov) - May 14, 2012
P3, N=612, Active, not recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: Mindfulness-Based Stress Reduction Techniques and Yoga for Treatment of Urinary Urge Incontinence (MBSR-Yoga) (clinicaltrials.gov) - May 13, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: Combined Spinal Epidural Urinary Retention (clinicaltrials.gov) - May 10, 2012
P=N/A, N=200, Recruiting, Sponsor: Northwestern University
- ||| valsartan / Generic mfg.
Enrollment change: To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 5, 2012
P4, N=509, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting N=700 --> 509
- |||| valsartan / Generic mfg.
Trial completion: To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 5, 2012
P4, N=509, Completed, Sponsor: Novartis
N=700 --> 509 Active, not recruiting --> Completed
- | New P4 trial: DERENEDIAB: Renal Denervation in Diabetic Nephropathy (clinicaltrials.gov) - Apr 29, 2012
P4, N=120, Recruiting, Sponsor: Assistance Publique - H
- Enrollment open: Vulvar Contact Dermatitis Resulting From Urine Incontinence (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=400, Recruiting, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- bortezomib / Generic mfg.
Trial withdrawal: Velcade for Proliferative Lupus Nephritis (clinicaltrials.gov) - Apr 22, 2012
P4, N=0, Withdrawn, Sponsor: The Rogosin Institute
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- bortezomib / Generic mfg.
Enrollment change: Velcade for Proliferative Lupus Nephritis (clinicaltrials.gov) - Apr 22, 2012
P4, N=0, Withdrawn, Sponsor: The Rogosin Institute
Recruiting --> Withdrawn N=14 --> 0
- epinephrine / Generic mfg.
Clinical: URINE&ME: Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=160, Recruiting, Sponsor: University of Massachusetts, Worcester
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: RALPIR: Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria (clinicaltrials.gov) - Apr 17, 2012
P4, N=20, Completed, Sponsor: Metropolis Medical
N=14 --> 0 Recruiting --> Completed
- Clinical: Effect of Pelvic Floor Muscle Training Included in General Fitness Classes During Pregnacy (clinicaltrials.gov) - Apr 10, 2012
P=N/A, N=169, Completed, Sponsor: Universidad Politecnica de Madrid
- Enrollment change: InterStim Therapy Programming Study (clinicaltrials.gov) - Apr 4, 2012
P=N/A, N=13, Completed, Sponsor: MedtronicNeuro
Recruiting --> Completed N=17 --> 13
- || Soliris (eculizumab) / AstraZeneca
Trial initiation date: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=75, Completed, Sponsor: Alexion Pharmaceuticals
N=17 --> 13 Initiation date: Sep 2011 --> Mar 2012
- ||||| iltamiocel (AMDC-USR) / Cook MyoSite
Trial initiation date: Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study (clinicaltrials.gov) - Mar 27, 2012
P3, N=246, Recruiting, Sponsor: Cook MyoSite
Initiation date: Sep 2011 --> Mar 2012 Initiation date: Sep 2011 --> Dec 2011
- Trial completion, Surgery: Value of Urodynamic Evaluation (clinicaltrials.gov) - Mar 11, 2012
P4, N=630, Completed, Sponsor: New England Research Institutes
Initiation date: Sep 2011 --> Dec 2011 Active, not recruiting --> Completed
- ||| Enrollment closed: TVTOxTVTS: TVTO (clinicaltrials.gov) - Mar 8, 2012
P4, N=124, Active, not recruiting, Sponsor: Federal University of S
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| emapticap pegol (NOX E36) / TME Pharma
New P2a trial: NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria (clinicaltrials.gov) - Mar 6, 2012
P2a, N=76, Completed, Sponsor: NOXXON Pharma AG
- | Rituxan (rituximab) / Roche
Trial initiation date: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Mar 5, 2012
P2/3, N=40, Recruiting, Sponsor: University of Miami
Enrolling by invitation --> Active, not recruiting Initiation date: Aug 2010 --> Mar 2012
- | Rituxan (rituximab) / Roche
Enrollment open: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Mar 5, 2012
P2/3, N=40, Recruiting, Sponsor: University of Miami
Initiation date: Aug 2010 --> Mar 2012 Not yet recruiting --> Recruiting
- Trial initiation date: Male Stress Urinary Incontinence and Sexual Health (clinicaltrials.gov) - Feb 23, 2012
P=N/A, N=50, Terminated, Sponsor: Stanford University
Not yet recruiting --> Recruiting Initiation date: Jun 2011 --> Oct 2011
- Enrollment change: Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence (clinicaltrials.gov) - Feb 22, 2012
P3, N=0, Withdrawn, Sponsor: Copenhagen University Hospital at Herlev
Initiation date: Jun 2011 --> Oct 2011 N=120 --> 0
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment open: Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) (clinicaltrials.gov) - Feb 14, 2012
P3, N=380, Recruiting, Sponsor: NICHD Pelvic Floor Disorders Network
N=120 --> 0 Not yet recruiting --> Recruiting
- Tekturna (aliskiren) / PDL
New P4 trial: The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria (clinicaltrials.gov) - Feb 10, 2012
P4, N=20, Completed, Sponsor: Medical University of Gdansk